{"id":"NCT00312208","sponsor":"Sanofi","briefTitle":"Docetaxel in Breast Cancer","officialTitle":"A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment of Operable Breast Cancer HER2neu Negative Patients With Positive Axillary Lymph Nodes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-11","primaryCompletion":"2008-10","completion":"2013-10","firstPosted":"2006-04-07","resultsPosted":"2010-02-17","lastUpdate":"2013-12-30"},"enrollment":3299,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"docetaxel, doxorubicin, cyclophosphamide","otherNames":[]},{"type":"DRUG","name":"Docetaxel,doxorubicin, cyclophosphamide","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"Primary objective :\n\n* To compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to doxorubicin and cyclophosphamide followed by docetaxel in operable adjuvant breast cancer HER2neu negative patients with positive axillary lymph nodes.\n\nSecondary objectives :\n\n* To compare toxicity and quality of life between the 2 above-mentioned arms.\n* To evaluate pathologic and molecular markers for predicting efficacy.","primaryOutcome":{"measure":"Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival)","timeFrame":"Median follow-up 65 months","effectByArm":[{"arm":"Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)","deltaMin":356,"sd":null},{"arm":"Docetaxel + Doxorubicin and Cyclophosphamide (TAC)","deltaMin":352,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.978"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":15},"locations":{"siteCount":37,"countries":["United States","Argentina","Australia","Belgium","Bosnia and Herzegovina","Brazil","Bulgaria","Canada","China","Colombia","Croatia","Cyprus","Czechia","Egypt","Estonia","France","Germany","Greece","Hong Kong","Hungary","Ireland","Israel","Lebanon","Mexico","New Zealand","Poland","Portugal","Romania","Russia","Saudi Arabia","Slovenia","South Africa","South Korea","Spain","Taiwan","Uruguay","Venezuela"]},"refs":{"pmids":["27573653","26940688"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":331,"n":1634},"commonTop":["Alopecia","Nausea","Asthenia","Neutropenia","Stomatitis"]}}